professional time and increasing productivity, improving access and equity, and reducing costs. However, before their systematic review of the conditions for health technology assessment (HTA) of one of the first commercially available chimeric antigen receptor (CAR) T-cell therapies, tisagenlecleucel. CAR T-cells are a major advance in personalized cancer treatment, demonstrating promising outcomes in relapsed/refractory pediatric acute lymphoblastic leukemia (pALL). However, the results are based on short-term follow up, limiting their value in predicting long-term survival and leading to uncertainty about the most appropriate survival modeling method to employ. This study aimed to address these limitations by means of expert elicitation.

Methods. An expert elicitation method, the histogram technique, was employed. A predefined discrete numerical scale was presented in Microsoft Excel and the expert was asked to place twenty crosses on a frequency chart. These crosses represented the expert’s beliefs about the distribution of particular quantities. Each cross represented five percent of the probabilistic distribution. Individual distributions were then aggregated across experts using linear pooling.

Results. A total of seventeen experts were invited to take part; eight agreed to participate and five completed the exercise. Three experts did not consider tisagenlecleucel to be a “curative” therapy because patients had a higher risk of death, compared with the age- and sex-matched general population. The aggregated distributions indicated the five-year overall survival rate to be thirty-three percent (95% CI 2.38 -52.04) in those who do not receive a subsequent stem cell transplant and twenty percent (95% CI 3.82 -52.04) in those who do.

Conclusions. The results of this study will be used to calibrate CD19 CAR T-cell therapy survival estimates presented in HTA submissions to the NCPE to ensure more robust assessments. They will also be used to inform the construction of a de novo cost-utility model for examining the cost effectiveness of CD19 CAR T-cell therapies for relapsed/refractory pALL in the Irish healthcare setting.

OP230 How Legitimate Is The Process Of Updating the Benefits Package In Israel? A 20 Year Overview

Dan Greenberg (danger@bgu.ac.il) and Yael Assor

Introduction. The National Health Insurance Law enacted in 1995 stipulates a minimum list of health services (benefits package) that the four health plans in Israel have to provide to their members. The recommendations on which new technologies or new indications for existing ones should be added every year to the benefits package, subject to a predetermined budget, are made by a public committee that evaluates and prioritizes candidate technologies according to their clinical merit, economic (mainly budget impact), social, ethical and other aspects. We assessed the legitimacy of this coverage decision process over the past 20 years.

Methods. The legitimacy of the process was assessed by adherence to the conditions outlined in the accountability for reasonableness (A4R) framework. A4R defines four conditions for legitimate and fair healthcare coverage decision processes: relevance, publicity, appeals/reversibility, and enforcement. We reviewed the changes made in the coverage decision process over the past 20 years and examined whether these changes have changed its legitimacy.

OP184 Strengthening Patient Outcome Evidence In Health Technology Assessments: A Co-Production Approach

Mark Rasburn (mark.rasburn@nice.org.uk), Heidi Livingstone and Gillian Leng

Introduction. Involving patients is a core principle which governs the work of the National Institute for Health and Care Excellence (NICE). To improve how patient evidence is identified and considered in health technology assessments (HTAs), NICE worked with patient organizations to review existing HTA methods and co-designed proposals for change.

Methods. A working group, including six patient organizations, oversaw the project, identifying and co-designing options for improvement. We held a stakeholder event with twenty-two patient organizations to identify themes for improving how we find and use patient evidence. We then ran an online quantitative and qualitative survey for targeted consultation with patient organizations to capture broader views.

Results. The fifty-two people who responded to the consultation made the following suggestions:

(i) Provide information about uncertainties that patient evidence might help to address;
(ii) Explore the role of real-world evidence in patient involvement;
(iii) Provide training and support to patient organizations;
(iv) Create inclusive committee cultures; and
(v) Include additional touchpoints during HTAs to incorporate patient evidence.

Conclusions. This work identified improvements in seeking and incorporating patient evidence into HTA processes. Precise guidance for patient organizations will help them to submit evidence that will make the most impact. This is particularly important when assessing disruptive technologies where there are likely to be greater uncertainties and cost pressures. The results of this work will be developed into formal options for NICE to consider when updating its methods guides.

OP206 Expert Elicitation Of Probabilistic Distributions to Inform Survival Modelling of CD19 Chimeric Antigen Receptor T-Cell Therapies

Niamh Carey (nicarey@tcd.ie), Conor Hickey, Laura Mc Cullagh and Michael Barry

Introduction. In 2018, the National Centre for Pharmacoeconomics (NCPE) was commissioned to conduct a